Le Lézard
Classified in: Health, Business
Subject: FDA

STERIBITE® Announces FDA Clearance of the Steribite Disposable Kerrison Rongeur


CLEVELAND, Nov. 13, 2018 /PRNewswire/ -- STERIBITE, LLC, a medical device company focused on developing unique, disposable surgical instruments, today announced it has received 510(k) clearance from the FDA to market its first product, the patented STERIBITE DISPOSABLE KERRISON RONGUER.  

Kerrison rongeurs are instruments used to remove bone on all spine procedures and are critical in one of the stages of the operation; however reusable Kerrison rongeurs are difficult to clean, raising the risk of possible infection to the patients.  They are also expensive and difficult to maintain and keep sharp, which is frustrating for spine surgeons and increases the risk for patients.

STERIBITE, LLC Chief Executive Officer John A. Redmond offers: "We are extremely pleased with the FDA clearance and know the STERIBITE disposable kerrison will provide a simple, safe and cost effective solution to the problems associated with reusable kerrison rongeurs.  We set out to create a better designed rongeur that eliminates all the problems associated with reusable ones, with the added safety of being totally disposable, and I am confident we have succeeded.  We look forward to introducing this exciting product in the U.S. early in the first quarter of 2019."

STERIBITE, LLC is a privately held medical device company and was developed by RJR Surgical, Inc., a Cleveland, Ohio based company.

CONTACT:
John A. Redmond
Chief Executive Officer
http://www.gen2medical.com 
1.866.241.2104

SOURCE STERIBITE, LLC


These press releases may also interest you

at 02:05
PureTech Health plc ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results...

at 02:05
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024      Strong commercial...

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...

at 00:00
Health Carousel, renowned for its dedication to enhancing the healthcare staffing sector, today unveiled its groundbreaking 'Full Circle of Support' program. This initiative represents a significant investment in the total well-being of its...

17 avr 2024
TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

17 avr 2024
SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM and 1st Credentialing, is providing notice of a recent data security event that may affect the security of information related to certain individuals. SysInformation is...



News published on and distributed by: